International Stem Cell Corporation

Equities

ISCO

US4603782016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 09:58:22 20/05/2024 pm IST			5-day change	1st Jan Change
0.09 ^USD	0.00%		0.00%	+45.16%

28/03	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 15, 2022 at 02:32 am IST

International Stem Cell Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 0.343 million compared to USD 0.165 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.02 a year ago.
For the nine months, net loss was USD 0.354 million compared to USD 0.548 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.07 a year ago.

Latest news about International Stem Cell Corporation

International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agrees to Extend (Until September 15, 2024) the Maturity Date of the Loan	18/23/18	CI
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial	28/23/28	RE
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Bayer claims early lead in Parkinson's stem cell therapy	28/23/28	RE
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	13/23/13	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	30/23/30	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	13/22/13	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Earnings Flash (ISCO) INTERNATIONAL STEM CELL CORPORATION Reports Q4 Loss $-0.11	30/22/30	MT
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	29/22/29	CI
International Stem Cell Corporation Announces Resignation of Sophia Garnette as Principal Financial Officer and VP of Legal Affairs and Operations, Effective April 1, 2022	02/22/02	CI
International Stem Cell Corporation announced that it has received $0.25 million in funding	13/22/13	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	13/21/13	CI
International Stem Cell Corporation and S Real Estate Holdings, Llc Enters into Lease Agreement with Rehco Holdings	02/21/02	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	14/21/14	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	15/21/15	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	31/21/31	CI
International Stem Cell Corporation announced that it has received $0.35 million in funding	05/21/05	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agreed to Extend Maturity Date of the Loan Until January 15, 2022	20/21/20	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	13/20/13	CI

Chart International Stem Cell Corporation

Duration

Period

Chart International Stem Cell Corporation

More charts

Company Profile

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTERNATIONAL STEM CELL CORPORATION	+45.16%	7L
MODERNA, INC.	+41.79%	5.09TCr
IQVIA HOLDINGS INC.	-0.56%	4.21TCr
LONZA GROUP AG	+49.62%	4.2TCr
CELLTRION, INC.	-7.20%	2.92TCr
ICON PUBLIC LIMITED COMPANY	+12.59%	2.6TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	1.89TCr
BIO-TECHNE CORPORATION	+6.92%	1.32TCr
UNITED THERAPEUTICS CORPORATION	+24.91%	1.22TCr
MEDPACE HOLDINGS, INC.	+29.60%	1.22TCr

Other Biotechnology & Medical Research